RPCA
OLMA icon

Running Point Capital Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Running Point Capital Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$24.5K – 192
2022
Q4 		$24.5K Hold
10,000
– – 0.02% 182
2022
Q3 		$28K Hold
10,000
– – 0.02% 171
2022
Q2 		$41K Hold
10,000
– – 0.03% 162
2022
Q1 		$43K Buy
+10,000
New +$55.1K 0.03% 162

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Running Point Capital Advisors's OLMA Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Olema Pharmaceuticals (OLMA) in Q1 2023, closing a stake of 10,000 shares — an estimated $24.5K sold.

Running Point Capital Advisors first reported a position in OLMA in Q1 2022 and held it in 4 quarters. The position peaked at $43K in Q1 2022. 65 funds tracked by Wall St. Rank hold OLMA as of Q1 2023.

  • Running Point Capital Advisors reported no remaining Olema Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,000 Olema Pharmaceuticals shares in Q1 2023, an estimated $24.5K.
  • Running Point Capital Advisors first reported a position in Olema Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Running Point Capital Advisors's Olema Pharmaceuticals position peaked at $43K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.